Receptor Tyrosine Kinase Treatment Market size was valued at USD 66.18 billion in 2024 and is set to exceed USD 175.7 billion by 2037, registering over 7.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of receptor tyrosine kinase treatment is evaluated at USD 74.7 billion.
The growth of the market can be attributed by growing cases of cancer all around the world. According to the World Health Organization, nearly 10 million deaths, or nearly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally. Hence the demand for targeted therapies are growing. Targeted therapy includes tyrosine kinase inhibitors (TKIs). A targeted therapy lessens the harm done to healthy cells by locating and attacking particular cancer cell types. Hence, the adoption of TKIs is growing extensively. Further, among this the receptor tyrosine kinase treatment is popular. Cell growth and survival are two important processes that are regulated by receptor tyrosine kinase (RTK) activity. But it has been demonstrated that dysregulation of RTK correlates with the onset and spread of many malignancies, and it has been discovered in a variety of tumors. As a result, RTK has gained popularity as a therapeutic target.
Additionally, there has been growing initiatives taken to spread awareness regarding the diagnosis and availability of cancer treatment. Also, governments are initiating their efforts and making healthcare facilities accessible to people. Further, since there has been growing prevalence of cancer, the R&D activities are also on boost. Moreover, the market for receptor tyrosine kinase treatment is being driven by the existence of patient support programmes. A lot of public and private organizations are concentrating on offering monetary and medical support for the therapy of numerous cancer symptoms. As a result, a large number of patients are receiving the necessary care, which is growing the patient base. These initiatives aid patients in sticking to their treatment plans.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.8% |
|
Base Year Market Size (2024) |
USD 66.18 billion |
|
Forecast Year Market Size (2037) |
USD 175.7 billion |
|
Regional Scope |
|
The global receptor tyrosine kinase treatment market is segmented and analyzed for demand and supply by application into lung cancer, breast cancer, renal cell cancer, and others. Out of which the breast cancer segment is anticipate to hold the largest market share over the forecast period. The growth of the segment can be attributed to growing cases of breast cancer all across the world. Breast cancer is the second most common type of cancer and the most common in females, with about 20% of all cases to be HER-2 positive. As a result, numerous HER2-targeted treatments have been introduced lately, including the TKIs lapatinib, neratinib, tucatinib, and pyrotinib. However, TKIs have proven to be successful in this situation where the outlook is still grim and there are few other therapy choices.
The global receptor tyrosine kinase treatment market is also segmented and analyzed for demand and supply by product type into epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, platelet-derived growth factor receptor (PDGFR) tyrosine kinase inhibitors, and others. Amongst these segments, the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors segment is anticipated to grow at the highest rate over the forecast period. This growth of the segment can be attributed to rising cases of lung cancer all across the world. Hence the demand for this treatment is estimated to increase has it has been observed to be one of the efficient treatment for lung cancer. Further, it is also used for treatment for various other cancers which includes, breast cancer, cervical cancer and more.
Our in-depth analysis of the global receptor tyrosine kinase treatment market includes the following segments:
|
By Product Type |
|
|
By Application |
|
|
By Distribution Channel |
|
North America Market Forecast
North America industry is likely to dominate majority revenue share of 40% by 2037, backed by high prevalence of cancer in the region, increasing R&D activities with tyrosine kinase inhibitors, and the presence of prominent market players, with the U.S. dominating over the region. In 2020, approximately 1.8 million new cases of cancer were diagnosed in the U.S. with a mortality rate higher among men than women. Additionally, there has been growing investment on R&D in order to develop novel cancer treatment in this region. Hence, this factor is also anticipated to boost the market growth in this region.
Asia-Pacific Market Forecast
Moreover, Asia-Pacific region is expected to witness the fastest market growth owing to the boost in prevalence of cancer all across this region. Between 2012 and 2018, the number of newly diagnosed cancer cases in Asia-Pacific rose from about 5 million to approximately 8 million. The region's population is ageing at a record-breaking rate, which is a major factor in this development. Hence, there has been rise in research and development activities for cancer and related diseases in this region, which is expected to boost the market further. Moreover, increased use of kinase inhibitors for newer applications in emerging economies such as China and India would provide new opportunities for market players to invest in the region, further boosting the market growth.
A study conducted provided information on the potential cardiotoxicity of a list of FDA approved Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and ranked them by their potential cardiotoxic risk associated in patients with solid tumors.
A research investigated the efficacy of EGFR-TKIs in older patients, where patients of 65 years or older with EGFR-mutated Stage IIIB–IV non-small-cell lung cancer (NSCLC) were enrolled and the efficacy and prognosis of first-line EGFR-TKI treatment was evaluated. EGFR-TKIs are standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?